{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T05:07:57Z","timestamp":1769836077512,"version":"3.49.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40273-025-01556-2","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:53:19Z","timestamp":1762365199000},"page":"207-218","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost Effectiveness of Efanesoctocog Alfa Versus Factor VIII Extended Half-Life in Adolescent and Adult Patients with Hemophilia A in the USA"],"prefix":"10.1007","volume":"44","author":[{"given":"Amy","family":"Dymond","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alix","family":"Arnaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ion","family":"Agirrezabal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Will","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"issue":"Suppl. 6","key":"1556_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl. 6):1\u2013158.","journal-title":"Haemophilia"},{"issue":"5","key":"1556_CR2","first-page":"378","volume":"17","author":"E Zanon","year":"2019","unstructured":"Zanon E, Pasca S. Intracranial haemorrhage in children and adults with haemophilia A and B: a literature review of the last 20 years. Blood Transfus. 2019;17(5):378\u201384.","journal-title":"Blood Transfus"},{"issue":"Suppl. 6","key":"1556_CR3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/hae.13449","volume":"24","author":"LFD van Vulpen","year":"2018","unstructured":"van Vulpen LFD, Holstein K, Martinoli C. Joint disease in haemophilia: pathophysiology, pain and imaging. Haemophilia. 2018;24(Suppl. 6):44\u20139.","journal-title":"Haemophilia"},{"key":"1556_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2147\/JBM.S103796","volume":"8","author":"K Lieuw","year":"2017","unstructured":"Lieuw K. Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches? J Blood Med. 2017;8:67\u201373.","journal-title":"J Blood Med."},{"issue":"10","key":"1556_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24108584","volume":"24","author":"AG Sarafanov","year":"2023","unstructured":"Sarafanov AG. Plasma clearance of coagulation factor VIII and extension of its half-life for the therapy of hemophilia A: a critical review of the current state of research and practice. Int J Mol Sci. 2023;24(10):8584.","journal-title":"Int J Mol Sci"},{"issue":"16","key":"1556_CR6","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1182\/blood-2016-04-713289","volume":"128","author":"SW Pipe","year":"2016","unstructured":"Pipe SW, Montgomery RR, Pratt KP, Lenting PJ, Lillicrap D. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A. Blood. 2016;128(16):2007\u201316.","journal-title":"Blood"},{"issue":"13","key":"1556_CR7","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1182\/blood.2020005673","volume":"137","author":"R Klamroth","year":"2021","unstructured":"Klamroth R, Windyga J, Radulescu V, Collins PW, Stasyshyn O, Ibrahim HM, et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood. 2021;137(13):1818\u201327.","journal-title":"Blood"},{"issue":"7","key":"1556_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12601","volume":"5","author":"HL Sun","year":"2021","unstructured":"Sun HL, Yang M, Poon MC, Lee A, Robinson KS, Sholzberg M, et al. The impact of extended half-life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B. Res Pract Thromb Haemost. 2021;5(7):e12601.","journal-title":"Res Pract Thromb Haemost"},{"issue":"Suppl. 1","key":"1556_CR9","first-page":"E12787","volume":"6","author":"J Oldenburg","year":"2022","unstructured":"Oldenburg J, Hay C, Peyvandi F, Tagliaferri A, Holme P, Alvarez-Rom\u00e1n M, et al. Recombinant factor VIII Fc showed better prophylactic effectiveness compared to standard half-life factor VIII in haemophilia A: results from A-SURE, a 24-month prospective, non-interventional study. Res Pract Thromb Haemost. 2022;6(Suppl. 1):E12787.","journal-title":"Res Pract Thromb Haemost."},{"issue":"8","key":"1556_CR10","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/ajh.25844","volume":"95","author":"LM Malec","year":"2020","unstructured":"Malec LM, Cheng D, Witmer CM, Jaffray J, Kouides PA, Haley KM, et al. The impact of extended half-life factor concentrates on prophylaxis for severe hemophilia in the United States. Am J Hematol. 2020;95(8):960\u20135.","journal-title":"Am J Hematol"},{"issue":"6","key":"1556_CR11","doi-asserted-by":"publisher","first-page":"819","DOI":"10.7326\/ANNALS-24-02749","volume":"178","author":"S Ito","year":"2025","unstructured":"Ito S, Potnis KC, Harvey JP, Sra M, Bewersdorf JP, Bona RD, et al. Prophylactic weekly efanesoctocog alfa versus standard-care factor VIII in people living with severe hemophilia A: a cost-effectiveness analysis. Ann Intern Med. 2025;178(6):819\u201328.","journal-title":"Ann Intern Med"},{"key":"1556_CR12","unstructured":"Tice J, Walton S, Herce-Hagiwara B, Fahim S, Moradi A, Sarker J, et al. Gene therapy for hemophilia B and an update on gene therapy for hemophilia A: effectiveness and value. Institute for Clinical and Economic Review. 2022. Available from: https:\/\/icer.org\/wp-content\/uploads\/2022\/05\/ICER_Hemophilia_Final_Report_12222022.pdf. Accessed 14 Feb 2024."},{"key":"1556_CR13","unstructured":"Roche. FDA approves Roche\u2019s Hemlibra (emicizumab-kxwh) for haemophilia A with inhibitors. 2017. Available from: https:\/\/www.roche.com\/media\/releases\/med-cor-2017-11-16. Accessed 14 Feb 2024."},{"key":"1556_CR14","unstructured":"US Food and Drug Administration. Hympavzi (marstacimab-hncq): highlights of Prescribing information. 2024. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761369s000lbl.pdf. Accessed 1 Jul 2025."},{"key":"1556_CR15","unstructured":"US Food and Drug Administration. QFITLIA (fitusiran): highlights of prescribing information. 2025. Available from: https:\/\/products.sanofi.us\/qfitlia\/qfitlia.pdf. Accessed 1 Jul 2025."},{"issue":"5","key":"1556_CR16","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.transci.2019.08.010","volume":"58","author":"AD Sankar","year":"2019","unstructured":"Sankar AD, Weyand AC, Pipe SW. The evolution of recombinant factor replacement for hemophilia. Transfus Apher Sci. 2019;58(5):596\u2013600.","journal-title":"Transfus Apher Sci"},{"key":"1556_CR17","unstructured":"Genentech. Hemlibra: highlights of prescribing information. 2024. Available from: https:\/\/www.gene.com\/search?q=hemlibra_prescribing&site=www.gene.com. Accessed 19 Feb 2024."},{"issue":"7","key":"1556_CR18","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1016\/j.jtha.2024.04.001","volume":"22","author":"B Madan","year":"2024","unstructured":"Madan B, Ozelo MC, Raheja P, Symington E, Quon DV, Leavitt AD, et al. Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A. J Thromb Haemost. 2024;22(7):1880\u201393.","journal-title":"J Thromb Haemost"},{"issue":"8","key":"1556_CR19","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1056\/NEJMoa2211075","volume":"388","author":"J Mahlangu","year":"2023","unstructured":"Mahlangu J, Kaczmarek R, von Drygalski A, Shapiro S, Chou SC, Ozelo MC, et al. Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A. N Engl J Med. 2023;388(8):694\u2013705.","journal-title":"N Engl J Med"},{"issue":"4","key":"1556_CR20","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1182\/bloodadvances.2021006119","volume":"6","author":"T Lissitchkov","year":"2022","unstructured":"Lissitchkov T, Willemze A, Katragadda S, Rice K, Poloskey S, Benson C. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. Blood Adv. 2022;6(4):1089\u201394.","journal-title":"Blood Adv"},{"issue":"11","key":"1556_CR21","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/NEJMoa2002699","volume":"383","author":"BA Konkle","year":"2020","unstructured":"Konkle BA, Shapiro AD, Quon DV, Staber JM, Kulkarni R, Ragni MV, et al. BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A. N Engl J Med. 2020;383(11):1018\u201327.","journal-title":"N Engl J Med"},{"issue":"17","key":"1556_CR22","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1182\/blood.2019001292","volume":"135","author":"E Seth Chhabra","year":"2020","unstructured":"Seth Chhabra E, Liu T, Kulman J, Patarroyo-White S, Yang B, Lu Q, et al. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of Von Willebrand Factor in primates and mice. Blood. 2020;135(17):1484\u201396.","journal-title":"Blood"},{"key":"1556_CR23","unstructured":"US Food and Drug Administration. Altuviio (efanesoctocog alfa): prescribing information. 2023. Available from: https:\/\/www.fda.gov\/media\/165594\/download. Accessed 14 Feb 2024."},{"key":"1556_CR24","unstructured":"US Food and Drug Administration. Altuviio: highlights of prescribing onformation. 2025. Available from: https:\/\/www.fda.gov\/media\/165594\/download. Accessed 25 Oct 2025."},{"issue":"4","key":"1556_CR25","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJMoa2209226","volume":"388","author":"A von Drygalski","year":"2023","unstructured":"von Drygalski A, Chowdary P, Kulkarni R, Susen S, Konkle BA, Oldenburg J, et al. Efanesoctocog alfa prophylaxis for patients with severe hemophilia A. N Engl J Med. 2023;388(4):310\u20138.","journal-title":"N Engl J Med"},{"issue":"6","key":"1556_CR26","first-page":"479","volume":"17","author":"L Aledort","year":"2019","unstructured":"Aledort L, Mannucci PM, Schramm W, Tarantino M. Factor VIII replacement is still the standard of care in haemophilia A. Blood Transfus. 2019;17(6):479\u201386.","journal-title":"Blood Transfus"},{"issue":"5","key":"1556_CR27","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1258\/rsmacta.43.5.528","volume":"43","author":"K Fischer","year":"2002","unstructured":"Fischer K, van Hout BA, van der Bom JG, Grobbee DE, van den Berg HM. Association between joint bleeds and Pettersson scores in severe haemophilia. Acta Radiol. 2002;43(5):528\u201332.","journal-title":"Acta Radiol"},{"issue":"1","key":"1556_CR28","first-page":"35","volume":"114","author":"A Tagliaferri","year":"2015","unstructured":"Tagliaferri A, Feola G, Molinari AC, Santoro C, Rivolta GF, Cultrera DB, et al. Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study. Thromb Haemost. 2015;114(1):35\u201345.","journal-title":"Thromb Haemost"},{"issue":"3","key":"1556_CR29","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/hae.13185","volume":"23","author":"A Coppola","year":"2017","unstructured":"Coppola A, D\u2019Ausilio A, Aiello A, Amoresano S, Toumi M, Mathew P, et al. Cost-effectiveness analysis of late prophylaxis vs. on-demand treatment for severe haemophilia A in Italy. Haemophilia. 2017;23(3):422\u20139.","journal-title":"Haemophilia"},{"key":"1556_CR30","unstructured":"Rind D, Walton S, Agboola F, Herron-Smith S, Quach D, Chapman R, et al. Valoctocogene roxaparvovec and emicizumab for hemophilia A: effectiveness and value; final report. Institute for Clinical and Economic Review. 2020. Available from: https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_Hemophilia-A_Final-Report_112020.pdf. Accessed 14 Feb 2024."},{"issue":"1","key":"1556_CR31","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12955-018-0908-9","volume":"16","author":"J O'Hara","year":"2018","unstructured":"O\u2019Hara J, Walsh S, Camp C, Mazza G, Carroll L, Hoxer C, et al. The impact of severe haemophilia and the presence of target joints on health-related quality-of-life. Health Qual Life Outcomes. 2018;16(1):84.","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"1556_CR32","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/rth2.12314","volume":"4","author":"F Kloosterman","year":"2020","unstructured":"Kloosterman F, Zwagemaker AF, Abdi A, Gouw S, Castaman G, Fijnvandraat K. Hemophilia management: huge impact of a tiny difference. Res Pract Thromb Haemost. 2020;4(3):377\u201385.","journal-title":"Res Pract Thromb Haemost"},{"key":"1556_CR33","unstructured":"Institute for Clinical and Economic Review. 2020\u20132023 value assessment framework. 2020. Available from: https:\/\/icer.org\/wp-content\/uploads\/2020\/11\/ICER_2020_2023_VAF_02032022.pdf. Accessed 14 Feb 2024."},{"issue":"6","key":"1556_CR34","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/hae.13023","volume":"22","author":"PM Poonnoose","year":"2016","unstructured":"Poonnoose PM, Hilliard P, Doria AS, Keshava SN, Gibikote S, Kavitha ML, et al. Correlating clinical and radiological assessment of joints in haemophilia: results of a cross sectional study. Haemophilia. 2016;22(6):925\u201333.","journal-title":"Haemophilia"},{"key":"1556_CR35","unstructured":"Clinical growth charts. National Center for Health Statistics. 2001. Available from: https:\/\/www.cdc.gov\/growthcharts\/html_charts\/wtage.htm. [Accessed 1 Oct 2023]."},{"key":"1556_CR36","first-page":"1","volume":"39","author":"CD Fryar","year":"2016","unstructured":"Fryar CD, Gu Q, Ogden CL, Flegal KM. Anthropometric reference data for children and adults: United States, 2011\u20132014. Vital Health Stat 3 Anal Stud. 2016;39:1\u201346.","journal-title":"Vital Health Stat 3 Anal Stud."},{"issue":"1","key":"1556_CR37","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s12325-024-03032-3","volume":"42","author":"R Klamroth","year":"2024","unstructured":"Klamroth R, Guyot P, Arnaud A, Wilson A, Wojciechowski P, Wdowiak M, et al. Efanesoctocog alfa versus standard and extended half-life factor VIII prophylaxis in adolescent and adult patients with haemophilia A without inhibitors. Adv Ther. 2024;42(1):427\u201341.","journal-title":"Adv Ther"},{"key":"1556_CR38","unstructured":"IBM Watson Health. Micromedex red book [database]. 2022. Available from: https:\/\/www.micromedexsolutions.com. Accessed 18 Sep 2023."},{"key":"1556_CR39","unstructured":"US Bureau of Labor Statistics. CPI inflation calculator. 2025. Available from: https:\/\/www.bls.gov\/data\/inflation_calculator.htm. Accessed 1 Jul 2025."},{"issue":"1","key":"1556_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13561-018-0185-7","volume":"8","author":"J O'Hara","year":"2018","unstructured":"O\u2019Hara J, Walsh S, Camp C, Mazza G, Carroll L, Hoxer C, et al. The relationship between target joints and direct resource use in severe haemophilia. Health Econ Rev. 2018;8(1):1.","journal-title":"Health Econ Rev."},{"issue":"5","key":"1556_CR41","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/13696998.2020.1721508","volume":"23","author":"K Cook","year":"2020","unstructured":"Cook K, Forbes SP, Adamski K, Ma JJ, Chawla A, Garrison LP Jr. Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A. J Med Econ. 2020;23(5):501\u201312.","journal-title":"J Med Econ"},{"issue":"2","key":"1556_CR42","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000679","volume":"6","author":"RMT Ten Ham","year":"2022","unstructured":"Ten Ham RMT, Walker SM, Soares MO, Frederix GWJ, Leebeek FWG, Fischer K, et al. Modeling benefits, costs, and affordability of a novel gene therapy in hemophilia A. Hemasphere. 2022;6(2):e679.","journal-title":"Hemasphere"},{"issue":"6","key":"1556_CR43","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.jval.2012.05.005","volume":"15","author":"EJ Neufeld","year":"2012","unstructured":"Neufeld EJ, Recht M, Sabio H, Saxena K, Solem CT, Pickard AS, et al. Effect of acute bleeding on daily quality of life assessments in patients with congenital hemophilia with inhibitors and their families: observations from the dosing observational study in hemophilia. Value Health. 2012;15(6):916\u201325.","journal-title":"Value Health"},{"issue":"7","key":"1556_CR44","doi-asserted-by":"publisher","first-page":"A593","DOI":"10.1016\/j.jval.2016.09.1420","volume":"19","author":"G Mazza","year":"2016","unstructured":"Mazza G, O\u2019Hara J, Carroll L, Camp C, Stentoft Hoxer C, Wilkinson L. PSY104 - The impact of haemophilia complications on health-related quality of life for adults with severe haemophilia. Value Health. 2016;19(7):A593.","journal-title":"Value Health"},{"key":"1556_CR45","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.2147\/PPA.S316276","volume":"15","author":"K Johnston","year":"2021","unstructured":"Johnston K, Stoffman JM, Mickle AT, Klaassen RJ, Diles D, Olatunde S, et al. Preferences and health-related quality-of-life related to disease and treatment features for patients with hemophilia A in a Canadian general population sample. Patient Prefer Adherence. 2021;15:1407\u201317.","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"1556_CR46","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","volume":"34","author":"P Vemer","year":"2016","unstructured":"Vemer P, Corro Ramos I, van Voorn GA, Al MJ, Feenstra TL. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics. 2016;34(4):349\u201361.","journal-title":"Pharmacoeconomics"},{"key":"1556_CR47","unstructured":"Institute for Clinical and Economic Review. ICER 2019 perspectives on cost-effectiveness threshold ranges. 2019. Available from: https:\/\/icer.org\/wp-content\/uploads\/2023\/08\/ICER_2019_Perspectives-on-Cost-Effectiveness-Threshold-Ranges.pdf. Accessed 1 Sep 2025."},{"issue":"6","key":"1556_CR48","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s40271-019-00374-x","volume":"12","author":"JR Wells","year":"2019","unstructured":"Wells JR, Gater A, Marshall C, Tritton T, Vashi P, Kessabi S. Exploring the impact of infusion frequency in hemophilia A: exit interviews with patients participating in BAY 94\u20139027 extension studies (PROTECT VIII). Patient. 2019;12(6):611\u20139.","journal-title":"Patient"},{"issue":"3","key":"1556_CR49","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/hae.13970","volume":"26","author":"Y Brennan","year":"2020","unstructured":"Brennan Y, Parikh S, McRae S, Tran H. The Australian experience with switching to extended half-life factor VIII and IX concentrates: on behalf of the Australian Haemophilia Centre Directors\u2019 Organisation. Haemophilia. 2020;26(3):529\u201335.","journal-title":"Haemophilia"},{"issue":"7","key":"1556_CR50","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/03007995.2022.2062180","volume":"38","author":"M Olivieri","year":"2022","unstructured":"Olivieri M, Simpson M, Yan S, Fedorovsky J, Zhang X, Tomic R, et al. Analysis of pooled real-world data from Germany, Italy, and the United States of rVIII-SingleChain compared with standard- and long-acting FVIII products for prophylaxis of hemophilia A. Curr Med Res Opin. 2022;38(7):1133\u20139.","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"1556_CR51","first-page":"1258","volume":"26","author":"S Yan","year":"2020","unstructured":"Yan S, Maro GS, Desai V, Simpson ML. A real-world analysis of commonly prescribed FVIII products based on U.S. medical charts: consumption and bleeding outcomes in hemophilia A patients. J Manag Care Spec Pharm. 2020;26(10):1258\u201365.","journal-title":"J Manag Care Spec Pharm"},{"key":"1556_CR52","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2147\/JBM.S359510","volume":"13","author":"Y Wu","year":"2022","unstructured":"Wu Y, Sun SX, Fan T. Comparison of real-world dose and consumption for two extended half-life recombinant factor VIII products for the treatment of hemophilia A in the United States. J Blood Med. 2022;13:517\u201324.","journal-title":"J Blood Med"},{"issue":"1","key":"1556_CR53","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2478\/jhp-2023-0002","volume":"10","author":"BS Dhal","year":"2023","unstructured":"Dhal BS, Dutta A, Borpatragohain D, Sharma A, Kashyap A. Clinical and radiological assessment of joints in people with haemophilia in Assam, Northeast India: a cross-sectional study. J Haemophilia Pract. 2023;10(1):11\u20139.","journal-title":"J Haemophilia Pract"},{"issue":"Suppl. 1","key":"1556_CR54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-207568","volume":"144","author":"J Staber","year":"2024","unstructured":"Staber J, Arnaud A, Agirrezabal I, Anson L, Wilson A, Kragh N, et al. Cost comparison of efanesoctocog alfa with existing factor VIII replacement therapies for major surgeries in people with severe hemophilia A. Blood. 2024;144(Suppl. 1):2582.","journal-title":"Blood"},{"issue":"14","key":"1556_CR55","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1182\/bloodadvances.2018021345","volume":"2","author":"N Machin","year":"2018","unstructured":"Machin N, Ragni MV, Smith KJ. Gene therapy in hemophilia A: a cost-effectiveness analysis. Blood Adv. 2018;2(14):1792\u20138.","journal-title":"Blood Adv"},{"issue":"4","key":"1556_CR56","doi-asserted-by":"publisher","first-page":"e267","DOI":"10.1111\/hae.13220","volume":"23","author":"A Shrestha","year":"2017","unstructured":"Shrestha A, Eldar-Lissai A, Hou N, Lakdawalla DN, Batt K. Real-world resource use and costs of haemophilia A-related bleeding. Haemophilia. 2017;23(4):e267\u201375.","journal-title":"Haemophilia"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01556-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-025-01556-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01556-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T16:02:50Z","timestamp":1769788970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-025-01556-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1556"],"URL":"https:\/\/doi.org\/10.1007\/s40273-025-01556-2","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"11 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Amy Dymond is an employee of York Health Economics Consortium who was paid consultancy fees by Sanofi. Alix Arnaud is an employee of Sanofi and may hold stock\/stock options in Sanofi. Ion Agirrezabal is an employee of Sanofi and may hold stock\/stock options in Sanofi. Will Green is an employee of York Health Economics Consortium who was paid consultancy fees by Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"All the source studies had ethical approval and were performed in accordance with the principles of the Declaration of Helsinki and local regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Patients were required to provide informed consent to participate in the source studies used in this post hoc analysis and modeling of data already collected.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Qualified researchers may request access to patient-level data and related study documents. Patient-level data will be anonymized, and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi\u2019s data-sharing criteria, eligible studies, and process for requesting access can be found at:\n                      \n                      .","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"AA, AD, IA, and WG made substantial contributions to the analysis and interpretation of the data. AA made substantial contributions to study conception and design and to the acquisition of data. All authors were involved in drafting the work or revising it critically for important intellectual content, and in final approval of the version to be published. All authors have agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Sobi and Sanofi reviewed and provided feedback on the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}